目的 探討腎元膠囊聯(lián)合阿魏酸哌嗪治療慢性腎炎的臨床療效。方法 選取2019年1月-2021年1月在漢中職業(yè)技術(shù)學(xué)院附屬醫(yī)院治療的116例慢性腎炎患者為研究對(duì)象，根據(jù)隨機(jī)數(shù)字表法分為對(duì)照組（58例）和治療組（58例）。對(duì)照組患者口服阿魏酸哌嗪膠囊，200 mg/次，3次/d。治療組患者在對(duì)照組基礎(chǔ)上口服腎元膠囊，5粒/次，3次/d。兩組患者均連續(xù)治療30 d。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀好轉(zhuǎn)時(shí)間、腎功能、尿蛋白、血漿白蛋白指標(biāo)，血清炎性因子白細(xì)胞介素6（IL-6）、白細(xì)胞介素2（IL-2）、腫瘤壞死因子α（TNF-α）和超敏C反應(yīng)蛋白（hs-CRP）水平及不良反應(yīng)情況。結(jié)果 治療后，治療組患者總有效率明顯高于對(duì)照組（98.28%vs 82.76%，P<0.05）。治療后，治療組患者臨床癥狀好轉(zhuǎn)時(shí)間均早于對(duì)照組（P<0.05）。治療后，兩組血漿尿素氮（BUN）、血漿肌酐（Scr）、24 h尿蛋白明顯低于治療前，而血漿白蛋白（Alb）指標(biāo)明顯升高（P<0.05），且治療組患者明顯好于對(duì)照組（P<0.05）。治療后，兩組血清炎性因子IL-6、TNF-α和hs-CRP水平明顯下降，而IL-2水平明顯升高（P<0.05），且治療組患者血清炎性因子水平明顯好于對(duì)照組（P<0.05）。治療組患者不良反應(yīng)發(fā)生率明顯低于對(duì)照組（8.62%vs 18.97%，P<0.05）。結(jié)論 腎元膠囊與阿魏酸哌嗪膠囊聯(lián)合治療慢性腎炎效果顯著，臨床癥狀好轉(zhuǎn)較快，能有效改善腎臟功能，并降低炎性反應(yīng)，且藥物安全有效。

Objective To investigate the curative effect of Shenyuan Capsules combined with piperazine ferulate in treatment of chronic nephritis. Methods Patients (116 cases) with chronic nephritis in the Affiliated Hospital of Hanzhong Vocational and Technical College from January 2019 to January 2021 were randomly divided into control (58 cases) and treatment (58 cases) groups according to random number table method. Patients in the control group were po administered with Piperazine Ferulate Capsules, 200 mg/time, three times daily. Patients in the treatment group were po administered with Shenyuan Capsules, 5 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, the improvement time of clinical symptoms, renal function, urine protein, albumin indexes, the serum inflammatory factors levels of IL-6, TNF-α, hs-CRP, and IL-2, and the drug adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was significantly higher than that of the control group (98.28% vs 82.76%, P<0.05). After treatment, the improvement time of clinical symptoms in the treatment group was earlier than that in the control group (P<0.05). After treatment, the levels of BUN, Scr, and 24-hour urinary protein in two groups were significantly lower than those before treatment, while the index of Alb in the treatment group was significantly higher than that in the control group (P<0.05), and these indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum inflammatory factors levels of IL-6, TNF-α, and hs-CRP in two groups were significantly decreased, while the level of IL-2 were significantly increased, and the level of serum inflammatory factors in the treatment group was significantly better than that in the control group (P<0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group (8.62% vs 18.97%, P<0.05). Conclusion The combined treatment of Shenyuan Capsules and Piperazine Ferulate Capsules has a significant effect, can quickly improve clinical symptoms, effectively improve the ability of renal function, and reduce inflammatory reaction, and the drug is safe and effective.

R983